Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Teva Pharmaceutical Industries
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Teva and mAbxience Announce Global Licensing Deal for an Oncology Biosimilar Candidate
Details : mAbxience will leverage its expertise in biosimilar development to develop and produce the biosimilar product currently in development for the treatment of multiple oncology indications.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 04, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Teva Pharmaceutical Industries
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Abbott Laboratories
Deal Size : Undisclosed
Deal Type : Agreement
Abbott Broadens Access to Cutting-edge Biosimilars in Key Emerging Markets
Details : Under the agreemeent, Abbott will commercialize several biosimilar molecules in key emerging markets in Latin America, Southeast Asia, the Middle East and Africa, and mAbxience will develop, manufacture and supply the biosimilar molecules.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 20, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Abbott Laboratories
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Iadademstat,Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Eurostars
Deal Size : $0.4 million
Deal Type : Funding
Details : ORY-1001 (iadademstat) is a small oral molecule, which acts as a highly selective inhibitor of the epigenetic enzyme LSD1 and has a powerful differentiating effect in hematologic cancers.
Product Name : ORY-1001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 16, 2022
Lead Product(s) : Iadademstat,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Eurostars
Deal Size : $0.4 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Xyphos Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The agreement covers VIVEbiotech long-term supplying lentiviral vectors for Xyphos’ upcoming clinical trial of its lead convertibleCAR-T™ program. This involves VIVEbiotech manufacturing lentiviral vectors for both preclinical and clinical phases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 06, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Xyphos Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration